This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dalbagni, G. Articles by Bajorin, D. Search for Related Content PubMed PubMed Citation Articles by Dalbagni, G. Articles by Bajorin, D. Social Bookmarking                            What's this?

Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the Bladder

From the Department of Urology; the Division of Epidemiology and Biostatistics; Pharmacology and Analytical Laboratory; and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Guido Dalbagni, MD, Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: dalbagng{at}mskcc.org

PURPOSE: The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder.

PATIENTS AND METHODS: Patients with superficial bladder cancer refractory to intravesical bacillus Calmette-Guérin (BCG) therapy and refusing a cystectomy were considered eligible for the trial. Gemcitabine was given in the bladder for 1 hour twice weekly in 100 mL sodium chloride for a total of six treatments. After a 1-week break, a second course of six treatments over 3 weeks was given, followed by response assessment. Four dose levels were explored: 500 mg, 1,000 mg, 1,500 mg, and 2,000 mg.

RESULTS: Eighteen patients completed therapy: three at 500 mg, six at 1,000 mg, three at 1,500 mg, and six at 2,000 mg. No grade 3 or 4 toxicity was observed at 500 mg. At 1,000 mg, three patients developed hematuria and one had a skin reaction resembling grade 3 hand-foot syndrome. Three patients at 1,500 mg had no grade 3 or 4 toxicity. Of six patients at 2,000 mg, one had grade 3 thrombocytopenia and neutropenia without infection. Seven patients had a complete response (negative cytology and posttreatment biopsy), and four patients had a mixed response (negative bladder biopsy but positive cytology).

CONCLUSION: Gemcitabine has substantial activity as an intravesical agent in BCG-refractory TCC and warrants further investigation. Therapy given twice weekly was associated with minimal bladder irritation and tolerable myelosuppression. The recommended phase II dose for twice-weekly therapy is 2,000 mg.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Addeo, M. Caraglia, S. Bellini, A. Abbruzzese, B. Vincenzi, L. Montella, A. Miragliuolo, R. Guarrasi, M. Lanna, G. Cennamo, et al. Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance J. Clin. Oncol., February 1, 2010; 28(4): 543 - 548. [Abstract] [Full Text] [PDF]

				M. H.A. Hussain, D. P. Wood, D. F. Bajorin, B. H. Bochner, R. Dreicer, D. L. Lamm, M. A. O'Donnell, A. O. Siefker-Radtke, D. Theodorescu, and C. P. Dinney Bladder Cancer: Narrowing the Gap Between Evidence and Practice J. Clin. Oncol., December 1, 2009; 27(34): 5680 - 5684. [Full Text] [PDF]

				D. J. Parekh, B. H. Bochner, and G. Dalbagni Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments J. Clin. Oncol., December 10, 2006; 24(35): 5519 - 5527. [Abstract] [Full Text] [PDF]

				G. Dalbagni, P. Russo, B. Bochner, L. Ben-Porat, J. Sheinfeld, P. Sogani, M. S. Donat, H. W. Herr, and D. Bajorin Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guerin-Refractory Transitional Cell Carcinoma of the Bladder J. Clin. Oncol., June 20, 2006; 24(18): 2729 - 2734. [Abstract] [Full Text] [PDF]

				W. Zoli, L. Ricotti, A. Tesei, P. Ulivi, A. G. Campani, F. Fabbri, R. Gunelli, G. L. Frassineti, and D. Amadori Schedule-Dependent Cytotoxic Interaction between Epidoxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro Clin. Cancer Res., February 15, 2004; 10(4): 1500 - 1507. [Abstract] [Full Text] [PDF]

				M. Laufer, S. Ramalingam, M. P. Schoenberg, M. E. Haisfield-Wolf, E. G. Zuhowski, I. N. Trueheart, M. A. Eisenberger, O. Nativ, and M. J. Egorin Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study J. Clin. Oncol., February 15, 2003; 21(4): 697 - 703. [Abstract] [Full Text] [PDF]

				E. D. Crawford Intravesical Therapy for Superficial Cancer: Need for More Options J. Clin. Oncol., August 1, 2002; 20(15): 3185 - 3186. [Full Text] [PDF]